National Institute of Allergy and Infectious Diseases (NIAID)

145 Protocols (125 Active Accrual of new subjects, 20 Follow-up of previously enrolled subjects)

 13-I-0141:

A Phase I Randomized, Double-Blind, Placebo-Controlled Study of a Multi-Antigen DNA Vaccine Prime Delivered by In Vivo Electroporation, rVSV Booster Vaccine in HIV-Infected Patients Who Began Antiretroviral Therapy During Acute/Early Infection

 13-I-0117:

Radiofrequency Ablation (RFA) for the Treatment of Liver Abscesses in Patients with Chronic Granulomatous Disease

 13-I-0094:

A Phase 1, Open-Label Study of Sirolimus in Eosinophil-Associated Gastrointestinal Disorders

 13-I-0082:

Rituximab (Anti-CD20) for the Treatment of Subjects With Anticytokine Autoantibody-Associated Diseases

 13-I-0081:

Phase 1 Study of Safety and Immunogenicity of Intranasal Ad4-H5-VTN in Ad4 Seronegative and Seropositive Volunteers

 13-I-0077:

An Open-Label, Phase 1 Study to Assess the Safety and Tolerability of Bone Marrow Stromal Cell Infusion for the treatment of Moderate to Severe Inflammatory Bowel Disease

 13-I-0075:

Sildenafil in Patients with Pulmonary Nontuberculous Mycobacterial Infection

 13-I-0066:

A Pilot Study to Evaluate the Safety and Efficacy of Multiple Anti-HCV Combination Therapy in Chronically Infected Hepatitis C Patients Who are Na ve or Null Responders to Peg-interferon Alpha Based Therapy

 13-I-0029:

A Phase 1, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of AVI-7100 in Healthy Subjects

 12-I-0184:

Use of Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for the Evaluation of Autoimmune Lymphoproliferative Syndrome Lymphadenopathy Suggestive of Lymphoma.

 12-I-0173:

A Long Term Follow-up Registry of Subjects Who Did Not Achieve Loss of S Antigen (HBsAg) and Sustained HBV Viral Load Reduction Below the Limitof Quantitation (BLQ) in Gilead-Sponsored Trials of GS-9620 in Subjects with Chronic Hepatitis B Infection

 12-I-0172:

Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Antiviral Activity of GS-9620 in Virologically Suppressed Subjects with Chronic Hepatitis B Virus Infection

 12-I-0171:

Single and Multiple-Dose Ranging Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Antiviral Activity of GS-9620 in Treatment Naive Subjects with Chronic Hepatitis B Viral Infection

 12-I-0157:

Clinical Outcomes in Persons with HIV Acquired Early in Life

 12-I-0142:

Transcriptional Signature of HIV And TB Co-Infection

 12-I-0133:

A Randomized, Double-Blind, Placebo Controlled Study of Liposomal Amikacin for Inhalation (Arikace(Registered Trademark)) in Patients with Recalcitrant Nontuberculous Mycobacterial Lung Disease

 12-I-0121:

Screening of Volunteers for Clinical Trials of Investigational and Licensed Vaccines, Antiviral Products, or Live Virus Challenge Studies

 12-I-0077:

Influenza A 2009 H1N1 Human Challenge Study in Healthy Adult Volunteers

 12-I-0026:

Assessment of Glucocorticoid Responsiveness and Mechanisms of Resistance in Hypereosinophilic Syndromes

 11-I-0259:

Phase 1 Study of Safety and Immunogenicity of Ad4-H5-VTN in Ad4 Seronegative and Seropositive Volunteers

 11-I-0253:

An Open Label, On-Treatment Trial to Assess the Effect of HIV-1 Coinfection on Therapeutic Responses using Boceprevir, Peg-Interferon-alfa-2b and Ribavirin in HCV Genotype 1, IFN Treatment-Naive Subjects with or without HIV-1

 11-I-0205:

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of DAS181 in Patients with Parainfluenza Infection

 11-I-0187:

The Natural History, Immunologic Correlates and Genetic Defects in Patients with Mucocutaneous and Invasive Fungal Infections

 11-I-0183:

Screening of Volunteers for Influenza Human Challenge Studies

 11-I-0164:

VRC 500:Screening of Volunteers for Clinical Trials of Investigational Products and Licensed Products Evaluated for Research Purposes

 11-I-0109:

Viral Infections in Healthy and Immunocompromised Hosts

 11-I-0057:

Effect of Interferon Alpha 2b Intensification on HIV-1 Residual Viremia in Individuals Suppressed on Antiretroviral Therapy

 11-I-0046:

Cross-Sectional Characterization of Idiopathic Bronchiectasis

 11-I-0031:

A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults

 11-I-0007:

Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age with X-Linked Severe Combined Immunodeficiency

 10-I-0216:

Studies of Disorders with Increased Susceptibility to Fungal Infections

 10-I-0210:

A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications

 10-I-0206:

Treatment of Mucocutaneous Leishmaniasis-Mucosal and/or Cutaneous Leishmaniasis-with Miltefosine

 10-I-0205:

Assessment of Alterations in Immune Function During Pregnancy and Post Parturition

 10-I-0197:

Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases

 10-I-0196:

Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders

 10-I-0195:

Training Protocol on the Natural History of Tuberculosis

 10-I-0148:

Natural History of Atopic Dermatitis and Other Genetic/Congenital Diseases Associated with Allergic Inflammation

 10-I-0139:

Searching for Persistence of Infection in Lyme Disease

 10-I-0123:

Assessment of the Biochemical Response to Interferon-Gamma in Subjects with Specific Gene Mutation in Chronic Granulomatous Disease

 10-I-0109:

VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older

 10-I-0101:

A Randomized, Placebo-controlled, Double-Blind Pilot Study of Single-Dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa Loa Infection

 10-I-0100:

A Pilot Study Using Anakinra/Kineret for the Treatment of Patients with Severe Atopic Dermatitis

 10-I-0095:

Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Normal Volunteers

 10-I-0080:

Cardiovascular Radiologic and Metabolic Assessment in HIV: An Investigation of Pathophysiology

 10-I-0043:

A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational anti-Influenza A Immune Plasma for the Treatment of Influenza A

 10-I-0029:

Non-Invasive Assessment of Atherosclerosis in Patients with CGD and Other Disorders of the Immune System

 10-I-0014:

The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients without Known Immunocompromise

 09-I-0246:

A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL Baxter) Against Tick-Borne Encephalitis (TBE) for NIAID Workers Manipulating Tick-Borne Encephalitis Virus (TBEV) in the Laboratory

 09-I-0226:

A Pilot Study for Collection of Anti-Influenza A Immune Plasma

 09-I-0200:

A Phase I Study of Mozobil (TM) in the Treatment of Patients with WHIMS

 09-I-0184:

Studies in the Pathogenesis of Systemic Capillary Leak Syndrome

 09-I-0172:

Natural History of Bronchiectasis

 09-I-0157:

Host Factors in Invasive and Recurrent Staphylococcus Aureus Infection

 09-I-0133:

Establishing Fibroblast-derived Cell Lines from Skin Biopsies of Patients with Immunodeficiency or Immunodysregulation Disorders

 09-I-0129:

A Randomized Double-Blinded, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis

 09-I-0126:

Pathogenesis of Physical Induced Urticarial Syndromes

 09-I-0108:

Strategic Timing of AntiRetroviral Treatment (START)

 09-I-0102:

Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

 09-I-0086:

Screening Protocol for Genetic Diseases of Allergic Inflammation and Mast Cell Homeostasis and Activation

 09-I-0069:

Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)

 09-I-0049:

Normal Blood, Bone Marrow and Buccal Mucosa Protocol

 09-I-0030:

Clinical and Immunologic Monitoring of Patients with Known or Suspected HIV Infection

 09-I-0013:

Biomarkers of Inflammation, Coagulation, and Endothelial Function in HIV-Infected Adults

 08-I-0221:

Analysis of HIV-1 Replication During Antiretroviral Therapy

 08-I-0184:

Studies in the Pathogenesis of Idiopathic Anaphylaxis

 07-I-0229:

Influenza in the Non-immunocompromised and Immunocompromised Host

 07-I-0183:

The Collection of Research Samples and/or Data for Repository from Related or Unrelated Hematopoietic Stem Cell Transplantation Recipients for the National Marrow Donor Program(Registered Trademark)

 07-I-0142:

Research Respiratory Tract Procedures

 07-I-0075:

Allogeneic and Matched Unrelated Donor Stem Cell Transplantation for Congenital Immunodeficiencies or Patients with Autoinflammatory/Immunodysregulatory Conditions: Busulfan-Based Conditioning with Campath- 1H or h-ATG, Radiation, and Sirolimus

 07-I-0033:

Screening Protocol for Detection and Characterization of Infections and Infection Susceptibility

 07-I-0017:

Autologous Transplantation of Genetically Modified Cells for the Treatment of X-Linked Chronic Granulomatous Disease

 06-I-0153:

A Pilot Study of Hepatic Fibrosis in HIV/AIDS Patients with Chronically Elevated Transaminases on Antiretroviral Therapy

 06-I-0086:

A Cohort Observational Study Evaluating Predictors, Incidence and Immunopathogenesis of Immune Reconstitution Syndrome (IRIS) in HIV-1 Infected Patients with CD4 Count Less Than or Equal to 100 Cells/microL Who Are Initiating Antiretroviral Therapy

 06-I-0049:

Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States

 06-I-0015:

Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death

 05-I-0219:

Microarray Analysis of Erythema Migrans Lesions

 05-I-0213:

Screening and Baseline Assessment of Patients with Abnormalities of Immune Function

 04-I-0286:

A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression

 04-I-0266:

Collection of Peripheral Blood and Bone Marrow From Healthy Donors for Use in In Vitro Research

 04-I-0086:

Evaluation of Clinical, Virologic and Immunologic Factors that Contribute to the Pathogenesis of Chronic Hepatitis C and its Complications

 03-I-0263:

Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies

 03-I-0090:

Immune Responses to Vaccinia Virus Vaccination

 03-I-0041:

Determining the Pathogenesis of Systemic Pediatric-Onset Mastocytosis

 02-I-0286:

A Pilot Study of the Safety and Efficacy of Imatinib Mesylate in Reducing Eosinophilia in Patients with the Myeloproliferative Variant Hypereosinophilic Syndrome (HES) or Non-Myeloproliferative HES Refractory to Standard Therapy

 02-I-0277:

Regulation of the Proliferation and Survival of Normal and Neoplastic Human Mast Cells

 02-I-0202:

Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-Infected Patients

 02-I-0147:

Genetic Studies of Chronic Active Epstein-Barr Virus Infection

 02-I-0110:

Natural History of Anthrax: A Study of Primary Infected, Recovered, and Exposed (SPoRE) Individuals and Evaluation of AVA Vaccinated Recipients

 02-I-0086:

Evaluation of Viral Factors and Immune Parameters to Study HIV-Specific Immunity

 02-I-0055:

Evaluation, Treatment and Follow up of Patients with Lyme Disease

 01-I-0238:

Diagnosis and Treatment of Leishmanial Infections

 01-I-0226:

Evaluation of Immune Response to Vaccines in Primary Immune Disorders

 01-I-0202:

Natural History, Genetics, Phenotype and Treatment of Mycobacterial Infections

 01-I-0161:

Identification of Novel Viruses

 01-I-0153:

The Immune Basis for the Gastrointestinal Complications of Common Variable Immunodeficiency

 00-I-0159:

Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)

 00-I-0099:

Langherhans' Cell Function and Inflammatory Responses in Skin of Volunteers Using the Suction Blister Technique

 99-I-0084:

To Develop a New Technique to Predict the Occurrence of Pneumocystis Pneumonia, Track its Epidemiology, Diagnose Acute Disease, and Predict and Monitor the Response to Various Therapeutic Agents

 98-I-0070:

Magnetic Resonance Imaging to Study Avascular Necrosis in HIV-Infected Subjects

Next 45 Protocols

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

National Institutes of Health Clinical Center
Bethesda, Maryland 20892. Last update: 05/18/2013